Zacks: Analysts Expect Heron Therapeutics Inc (HRTX) Will Announce Earnings of -$0.78 Per Share

Brokerages predict that Heron Therapeutics Inc (NASDAQ:HRTX) will report ($0.78) earnings per share for the current quarter, Zacks reports. Three analysts have issued estimates for Heron Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.64) and the lowest estimate coming in at ($0.91). Heron Therapeutics reported earnings per share of ($1.03) in the same quarter last year, which would suggest a positive year-over-year growth rate of 24.3%. The firm is scheduled to announce its next earnings report on Thursday, February 22nd.

On average, analysts expect that Heron Therapeutics will report full-year earnings of ($3.37) per share for the current financial year, with EPS estimates ranging from ($3.42) to ($3.30). For the next year, analysts forecast that the company will post earnings of ($2.22) per share, with EPS estimates ranging from ($2.93) to ($1.52). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.10. The company had revenue of $8.57 million during the quarter, compared to analyst estimates of $8.12 million. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%.

Several equities research analysts recently commented on HRTX shares. Mizuho reissued a “buy” rating and issued a $28.00 price target on shares of Heron Therapeutics in a report on Tuesday, January 16th. ValuEngine raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Leerink Swann started coverage on shares of Heron Therapeutics in a report on Tuesday, January 2nd. They issued an “outperform” rating and a $22.00 price target for the company. Cowen reissued a “buy” rating and issued a $40.00 price target on shares of Heron Therapeutics in a report on Wednesday, December 6th. Finally, Zacks Investment Research raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 8th. Three analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $28.82.

Shares of Heron Therapeutics (NASDAQ HRTX) traded down $0.25 during midday trading on Friday, reaching $21.65. 714,085 shares of the company traded hands, compared to its average volume of 1,070,000. The stock has a market cap of $1,180.00, a price-to-earnings ratio of -5.71 and a beta of 1.87. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.02 and a current ratio of 2.12. Heron Therapeutics has a 12 month low of $12.70 and a 12 month high of $24.80.

In other Heron Therapeutics news, VP Kimberly Manhard sold 7,584 shares of Heron Therapeutics stock in a transaction on Wednesday, January 10th. The shares were sold at an average price of $20.00, for a total transaction of $151,680.00. Following the sale, the vice president now owns 7,584 shares of the company’s stock, valued at approximately $151,680. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 19.93% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in HRTX. Fisher Asset Management LLC boosted its position in shares of Heron Therapeutics by 20.6% during the 4th quarter. Fisher Asset Management LLC now owns 121,069 shares of the biotechnology company’s stock valued at $2,191,000 after acquiring an additional 20,705 shares during the last quarter. Fox Run Management L.L.C. boosted its position in shares of Heron Therapeutics by 27.5% during the 4th quarter. Fox Run Management L.L.C. now owns 22,050 shares of the biotechnology company’s stock valued at $399,000 after acquiring an additional 4,750 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its position in shares of Heron Therapeutics by 50.7% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 242,934 shares of the biotechnology company’s stock valued at $4,398,000 after acquiring an additional 81,735 shares during the last quarter. Private Asset Management Inc. boosted its position in shares of Heron Therapeutics by 190.6% during the 4th quarter. Private Asset Management Inc. now owns 86,975 shares of the biotechnology company’s stock valued at $1,574,000 after acquiring an additional 57,050 shares during the last quarter. Finally, Rubric Capital Management LP boosted its position in shares of Heron Therapeutics by 11.8% during the 3rd quarter. Rubric Capital Management LP now owns 1,900,000 shares of the biotechnology company’s stock valued at $30,685,000 after acquiring an additional 200,000 shares during the last quarter. 98.34% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This report was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another publication, it was stolen and republished in violation of US & international copyright laws. The legal version of this report can be read at https://ledgergazette.com/2018/02/12/zacks-analysts-expect-heron-therapeutics-inc-hrtx-will-announce-earnings-of-0-78-per-share.html.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply